Tadalafil Tablet
Product Images NDC 76420-552

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 76420-552). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asclemed Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10mg (Tadalafil 10mg)

Packaging labels for Tadalafil Tablets USP 10 mg from Enovachem Pharmaceuticals, showing multiple package quantities including 30, 60, 90, 120, and 500 tablets. Labels include the NDC numbers, marketing by Ajanta Pharma USA Inc., and storage instructions. Each label features a QR code and indicates prescription drug status.*

FDA Label Image

2.5mg (Tadalafil 2 5mg)

Label images for Tadalafil Tablets USP 2.5 mg by Enovachem Pharmaceuticals, packaged in quantities of 30, 60, 90, 120, and 500 tablets. Labels include NDC codes, manufacturer Ajanta Pharma USA Inc., storage instructions, and federal law dispensing warnings. Each label features a barcode and state the tablets are light yellow to yellow and film-coated.*

FDA Label Image

20mg (Tadalafil 20mg)

Labels for Tadalafil Tablets, USP 20 mg, in various quantities including 30, 60, 90, 120, and 500 tablets. Packaged by Enovachem Pharmaceuticals, with marketing by Ajanta Pharma USA Inc. Each label includes NDC numbers, batch and lot information placeholders, and storage instructions. The tablets are described as light yellow to yellow oval-shaped, film-coated, debossed T20.*

FDA Label Image

5mg (Tadalafil 5mg)

Multiple packaging labels for Tadalafil Tablets USP 5 mg from Enovachem Pharmaceuticals. Labels indicate quantities of 30, 60, 90, 120, and 500 tablets. Marketed by Ajanta Pharma USA Inc. Each label includes the NDC code, storage instructions, cautionary statements, and packaging details. The labels are designed with black text on a white background and feature the Enovachem logo at the top.*

FDA Label Image

Figure8 (Tadalafil Fig8)

A line graph comparing the change from baseline in IPSS total score over 12 weeks between Tadalafil 5 mg and placebo groups. The x-axis represents duration of treatment in weeks, and the y-axis shows the change from baseline in IPSS score, with Tadalafil showing a greater decrease than placebo. Statistical significance (p<0.01) is noted at 12 weeks.*

FDA Label Image

Figure1 (Tadalafil Figure1)

Four line graphs depicting the change in blood pressure over time after Tadalafil administration compared to placebo. The charts show differences in standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressure across time points from 0 to 96 hours.*

FDA Label Image

Figure2 (Tadalafil Figure2)

Two line graphs showing the effect of Tadalafil 20 mg combined with doxazosin 8 mg versus placebo with doxazosin 8 mg on standing and supine systolic blood pressure over 24 hours post-dose. The y-axes measure systolic blood pressure change in mmHg, and the x-axes show time in hours post-dose.*

FDA Label Image

Figure3 (Tadalafil Figure3)

A line graph depicting changes in systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo combined with doxazosin dosed at 8 mg at 08:00. The graph compares four groups: 20 mg tadalafil with 8 mg doxazosin, placebo with 8 mg doxazosin, each administered either once at 08:00 or twice (08:00 and 20:00). Time after administration is shown on the x-axis and systolic BP change on the y-axis.*

FDA Label Image

Figure4 (Tadalafil Figure4)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose following 5 consecutive days of administration. The graph illustrates changes in tadalafil levels with error bars at each time point.*

FDA Label Image

Figure5 (Tadalafil Figure5)

A line graph depicting change from baseline in IPSS total score over 12 weeks of treatment. Two lines compare Tadalafil 5 mg and placebo, showing trends in score reduction over time at 0, 4, 8, and 12-week intervals.*

FDA Label Image

Figure6 (Tadalafil Figure6)

A line graph comparing the change from baseline in IPSS total score over a 12-week treatment duration for Tadalafil 5 mg and placebo. The graph shows Tadalafil 5 mg as a solid line with filled circles and placebo as a dashed line with open triangles. A statistically significant difference (p<0.01) is noted.*

FDA Label Image

Figure7 (Tadalafil Figure7)

A line graph showing least-squares mean change from baseline over 26 weeks of therapy comparing Tadalafil/Finasteride combination to Placebo/Finasteride. The vertical axis shows the change in baseline, and the horizontal axis represents weeks of therapy with data points at 0, 4, 12, and 26 weeks. The graph includes statistical significance markers (p<0.001, p<0.05) for differences observed.*

FDA Label Image

Structure (Tadalafil Structure)

Chemical structure of Tadalafil, a human prescription drug with oral tablet dosage form, depicting the molecular arrangement of atoms characteristic of the active ingredient Tadalafil.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.